Kura Oncology, Inc. Profile Avatar - Palmy Investing

Kura Oncology, Inc.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are…

Biotechnology
US, San Diego [HQ]
Financials

Analysts

Reported
Past Estimate Consensus
Future Estimate Consensus
Kura Oncology, Inc. can't present any analysts estimates at the moment detail analysis.
End of KURA's Analysis
CIK: 1422143 CUSIP: 50127T109 ISIN: US50127T1097 LEI: - UEI: -
Secondary Listings
KURA has no secondary listings inside our databases.